Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
Jul. 31, 2025 |
| Titan Pharmaceuticals Inc [Member] |
|
|
| Schedule of Deferred Tax Assets |
Schedule
of Deferred Tax Assets and Liabilities
| (in thousands of
U.S. dollars) | |
2025 | | |
2024 | |
| | |
As
of December
31, | |
| (in thousands of
U.S. dollars) | |
2025 | | |
2024 | |
| Deferred tax assets: | |
| | | |
| | |
| Net operating loss carryforwards | |
$ | 45,516 | | |
$ | 49,611 | |
| Research credit carryforwards | |
| 8,731 | | |
| 9,214 | |
| Other, net | |
| 895 | | |
| 1,655 | |
| Total deferred tax assets | |
| 55,142 | | |
| 60,480 | |
| Deferred tax liabilities: | |
| | | |
| | |
| Other, net | |
| - | | |
| - | |
| Total deferred tax liabilities | |
| - | | |
| - | |
| Valuation allowance | |
| (55,142 | ) | |
| (60,480 | ) |
| Net deferred tax assets | |
$ | - | | |
$ | - | |
|
|
| Schedule of Reconciliation Actual Benefit of (provision For) Income Taxes |
The
provision for income taxes is zero due to operating losses. The effective tax rate of our provision (benefit) for income taxes differs
from the federal statutory rate as follows:
Schedule
of Effective Tax Rate of Provision (Benefit) For Income Taxes
| (in thousands of
U.S. dollars) | |
2025 | | |
2024 | |
| | |
For the Years Ended December
31, | |
| (in thousands of
U.S. dollars) | |
2025 | | |
2024 | |
| Computed at 21% | |
$ | (522 | ) | |
$ | (980 | ) |
| State taxes | |
| - | | |
| (436 | ) |
| Change in valuation allowance | |
| (5,116 | ) | |
| (4,547 | ) |
| Other | |
| 171 | | |
| 1 | |
| Stock based compensation | |
| 273 | | |
| 74 | |
| Research and development credits | |
| (161 | ) | |
| (185 | ) |
| Tax attributes expirations | |
| 5,355 | | |
| 6,082 | |
| Impact of IRC 162m | |
| - | | |
| (8 | ) |
| Total | |
$ | - | | |
$ | 1 | |
|
|
| TALENTEC SDN. BHD. [Member] |
|
|
| Schedule of Deferred Tax Assets |
|
Deferred
tax assets have not been recognized in respect of the following items:
Schedule
of Deferred Tax Assets
| | |
2024 | | |
2025 | |
| | |
For
the years ended July 31, | |
| | |
2024 | | |
2025 | |
| Deferred
tax assets: | |
| | | |
| | |
| Net
operating loss carry-forwards | |
$ | 189,010 | | |
$ | 146,561 | |
| Total
deferred tax assets | |
| 189,010 | | |
| 146,561 | |
| Less:
Valuation allowance | |
| (189,010 | ) | |
| (146,561 | ) |
| Total
deferred tax assets, net | |
$ | - | | |
$ | - | |
|
| Schedule of Reconciliation Actual Benefit of (provision For) Income Taxes |
|
A
reconciliation between the Group’s actual provision for income taxes at the Malaysian statutory rate is as follows:
Schedule
of Reconciliation Actual Benefit of (provision For) Income Taxes
| | |
2024 | | |
2025 | |
| | |
For
the years ended July 31, | |
| | |
2024 | | |
2025 | |
| Income
tax expense at the statutory rate of 17% | |
| 26,049 | | |
| 35,685 | |
| Tax
effect of non-deductible expense | |
| 124 | | |
| 3,341 | |
| Tax
effect of other temporary differences | |
| 1,094 | | |
| (3,132 | ) |
| Unrecognized
deferred tax assets | |
| (25,871 | ) | |
| 8,575 | |
| Utilize
prior year tax losses which not recorded deferred tax assets | |
| (1,396 | ) | |
| (44,469 | ) |
| Income
taxes expense | |
$ | - | | |
$ | - | |
|
| Schedule of Components of Income Before Income Taxes |
|
The
components of loss/income before income taxes were comprised of the following:
Schedule
of Components of Income Before Income Taxes
| | |
2024 | | |
2025 | |
| | |
For
the years ended July 31, | |
| | |
2024 | | |
2025 | |
| Tax
jurisdictions from: | |
| | | |
| | |
| -Malaysia | |
$ | 145,017 | | |
$ | 260,353 | |
| -Singapore | |
| 8,210 | | |
| (50,442 | ) |
|
| Schedule of Provision for Income Taxes |
|
The
provision for income taxes consisted of the following:
Schedule
of Provision for Income Taxes
| | |
2024 | | |
2025 | |
| | |
For
the years ended July 31, | |
| | |
2024 | | |
2025 | |
| Current: | |
| | | |
| | |
| -Malaysia | |
$ | - | | |
$ | - | |
| -Singapore | |
| - | | |
| - | |
| Current | |
| - | | |
| - | |
| | |
| | | |
| | |
| Deferred: | |
| | | |
| | |
| -Malaysia | |
| - | | |
| - | |
| -Singapore | |
| - | | |
| - | |
| Deferred | |
| - | | |
| - | |
| Income
tax expense | |
$ | - | | |
$ | - | |
|
| Schedule of Changes in Valuation Allowance |
|
Changes
in valuation allowance are as follows:
Schedule
of Changes in Valuation Allowance
| | |
2024 | | |
2025 | |
| | |
For
the years ended July 31, | |
| | |
2024 | | |
2025 | |
| Balance
at the beginning of the year | |
$ | 242,146 | | |
$ | 189,010 | |
| Additions | |
| (1,396 | ) | |
| 8,575 | |
| Utilization | |
| (47,446 | ) | |
| (59,233 | ) |
| Foreign
exchange effect | |
| (4,294 | ) | |
| 8,208 | |
| Balance
at the end of the year | |
$ | 189,010 | | |
$ | 146,561 | |
|